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Abstract

L-tryptophan is the least common essential amino acid and is necessary for
cellular proliferation. In the context of immune regulation, lack o f tryptophan in tissue
microenvironments and the production of its bioactive metabolites has been implicated as
an immunosuppressive phenomenon. The rate limiting enzyme in tryptophan degradation
is indoleam ine 2,3 dioxygenase (EDO), which metabolizes tryptophan along the Lkynurenine pathway. W hen induced by interferon signaling, IDO promotes anergy and
apoptosis in naive T-cells, and enables the differentiation and activation of T-regulatory
cells. However, the role that IDO and tryptophan metabolism play in epitope specific
CD8+ T-lymphocyte (CTL) function has not yet been investigated. By using a
pharmacological inhibitor (1-methyl-D-tryptophan) and knockout (KO) mice
independently, IDO was depleted to examine its role in shaping the CTL responses to
SV40 large T antigen (TAg) and influenza A virus (IAV). EDO KO and inhibition
increased the frequency of CD8+ T-cells specific for defined epitopes in both models, as
measured by intracellular cytokine staining (ICS). This increase in cell frequency was
mediated by a proliferative advantage exhibited by immunodominant EDO KO T-cells
when compared with W T counterparts. Bioactive tryptophan metabolites such as Lkynurenine did not play a role in this system, and failed to decrease T-cell responses in
either the TAg or IAY model. In addition, IDO KO potentiated the cytotoxic effector
function of CTLs in vivo, but did not affect animal morbidity in a disease model of IAV
infection.

Keywords: tryptophan metabolism, CD8+ T-cells, immunodominance, IDO, influenza
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Tryptophan Metabolism and CD8+ T-cell Function

Introduction
CD8+ T-cell Antisen Recognition and Cytotoxicity
The main cytotoxic effectors of the adaptive immune system are CD8+ Tlymphocytes (CTLs), which use their T-cell receptor (TCR) to recognize peptide antigens
presented in the context of major histocompatibility complex class I (MHC I) molecules
on the surface of all nucleated host cells. MHC I is composed of a and non-variable Pamicroglobulin polypeptide chains, with the a l and a2 domains forming the peptide
binding groove, and a3 acting as the transmembrane region (Figure i) (1,2). Newly
synthesized MHC I a chains are assembled inside the endoplasmic reticulum (ER) of the
host cell where they associate with calnexin, which is a membrane bound protein. Upon
binding with P2-microglobulin, the MHC I complex disassociates from calnexin, and
interacts with a group of chaperone proteins to await delivery of an appropriate peptide
(3).
The CD8+ T-cell TCR which recognizes peptides presented in the MHC I
binding groove is composed of two protein subunits, a and p, which together form a
dim er that is embedded in the cellular membrane. The two subunits are further
subdivided into variable and constant chains, which function to recognize antigen, and
anchor the TCR into the cell membrane respectively. In addition, the TCR dimer is
usually associated with at least six other signalling subunits such as various CD3
heterodimers (o,y, e, etc.). In addition, CD8 molecules which bind to the non-variable

1
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Cell m em brane

Figure i - Major histocompatibility complex I (MHC I) structure
The MHC I molecule is composed of a and p polypeptide chains. The al+ a2 subunits form the
peptide binding pocket while a3 acts as the transmembrane domain. The p2-microglobulin domain
is invariant and binds to CD8 co-receptors on the TCR.
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Figure ii-T -ce ll receptor (TCR) complex structure
The TCR is composed of variable and constant regions within a and (3 subunits, that together form
the TCR dimer. This is accompanied by transmembrane heterodimeric CD3 receptors, as well as the
CD8 co-receptor.
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region o f MHC I, act as co-receptors and are also part of the TCR complex. There is
evidence which suggests that CD8 co-receptors modulate the “triggering” sensitivity of
the TCR, and regulate the affinity of cognate TCR:M HC I binding by affecting the
association/dissociation rate of these molecular interactions (Figure ii) (4,5).
The peptides presented to CD8+ T-cells by MHC I are usually derived from viral
and other foreign proteins that have been degraded by the proteasome system inside a
host cell. The MHC I molecule can accommodate peptides between 8-11 amino acids in
length, which are transported into the ER by the transporter associated with antigen
processing (TAP) protein in an ATP dependent manner, and then loaded onto MHC I in
the ER by the MHC I loading complex. The successfully loaded MHC I molecule is then
secreted to the cell membrane where it can present antigen to CTLs with the appropriate
TCR specificity (Figure iii) (6,7).
The antigen:MHC complex can activate naive CD8+ T-cells if it is accompanied
by co-stimulation in the form of ligation between CD28 on the T-cell and CD80/CD86
molecules on professional antigen presenting cells (APCs) such as dendritic cells (DCs)
(Figure iv). DCs engage in the ‘cross prim ing’ of naive CD8+ T-cells when they take up
and process antigenic material and express it in the context of their own MHC I
molecules. This is in contrast to ‘direct prim ing’, which involves the direct presentation
of viral peptides by virally infected host cells without the necessary involvement of DCs
(8,9).
Once activated, CTLs migrate to the lymph node where they undergo clonal
expansion and then disseminate throughout the body, killing cells that express the
recognized antigen:MHC complex. Target cells can be eliminated by CTLs through two
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Cytosol

Figure iii - Antigen processing and presentation in host cell
Cytoplasmic viral proteins are processed into short length peptides by the proteasome system.
These peptides are then transported into the ER by TAP, where they are loaded on MHC I
molecules. MHC l:Peptide complexes are shuttled to the cell membrane where they present antigen
to CTLs
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D endritic cell (DC)

/

Figure iv - Activation of naive CD8+ T-cells by DCs
Naive T-cells require both TCR recognition of MHC l.'Peptide complexes, as well as costimulation in
the form of CD28 ligation with CD80/CD86, in order to become activated

6

main mechanisms, namely Fas/Fas-L (CD95/CD95L) interactions as well as the
polarization and release of perforin and granzyme molecules at the immunological
synapse via the perforin pathway. Both mechanisms of CTL killing induce the caspase
cascade in the target host cell, leading to DNA fragmentation and subsequent death via
apoptosis (10,11).
Studies have shown that these two cytolytic pathways are complementary, and
CTLs may be able to clear virally infected cells in the absence of one o f the pathways but
not both (12). For instance, influenza A virus (IAV) infected, Fas negative epithelial cells
are still eliminated by W T CD8+ T-cells, while perforin negative CTLs can eliminate
IAV infected Fas positive epithelial cells. This suggests that either cytolytic mechanism
is sufficient for anti-viral immunity to IAV (12).
There also exists a degree of redundancy within the individual cytolytic pathways.
Though CTLs which lack granzyme B are unable to induce rapid DNA fragmentation in
virally infected cells, they will promote late onset DNA fragmentation if they still express
granzyme A (13). However, mice with a combined knockout of granzymes A and B
exhibit a severe cytolysis defect, similar to perforin KO mice, which suggests that
perforin alone is not sufficient to induce cell death and that a combination of perforin and
granzyme A or B is required (13).
It is necessary to note that the perforin/granzyme pathway, though important for
viral clearance, has also been linked to autoimmune CNS pathology during specific viral
infections. WT mice actually exhibit a higher risk of demyelination following intracranial
infection with a mouse coronavirus (JHMV) when compared with perforin KO mice.
The animals lacking perforin also exhibit lower morbidity and mortality at doses of virus
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that are lethal in W T mice. This suggests that although the perforin/granzyme pathway is
important for the clearance of certain viral infections, it also represents a double edged
sword that can exacerbate disease in certain contexts (14).
Another im portant manner through which activated CD8+ T-cells regulate viral
infections, independently of their cytotoxic functions, is via the secretion of immuno
modulatory cytokines such as IFN-y. For instance, the production of this cytokine by
CTLs has been linked to the increased recruitment of neutrophils to the site of antigen
challenge at the level of the skin (15). Furthermore, IFN-y production by CD8+ T-cells
also augments other aspects of the adaptive immune response, by inducing T-bet
dependent and independent class switching in B-cells in response to alum adjuvanted
vaccination (16). Importantly, IFN-y also directly influences the outcome of certain viral
infections, and CTLs require the secretion of this cytokine in order to efficiently clear
bom a disease vim s (BDV) in mice (17).

CD8+ T-cell Immunodominance
Despite the fact that thousands of potentially immunogenic peptides are produced
inside host cells during a viral infection, only a small percentage of these actually induce
detectable CTL responses in vivo. The relative immunogenicity of these epitopes varies
and can be arranged in a so called immunodominance hierarchy, which ranks the
antigenic determinants on the basis of their propensity to elicit CTL responses.
Immunodominant determinants are so termed because they are recognized by and
activate the largest percentage of CTLs, whilst subdominant epitopes induce responses in
a smaller population of T-cells. The reasons behind the phenomenon of
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immunodominance are an active field of research, with profound implications for CTL
immunobiology and vaccine design. If factors that augment the immunodominance
hierarchy of a given virus are identified, this will allow the generation of vaccines which
induce a broader spectrum of CTL immunity, and prevent the creation of a bottleneck
that will aid in viral escape (18).
There are a variety of explanations why only a select number of viral epitopes are
actually presented to and activate CTLs in an immunodominant hierarchy, and one of the
main contributors is peptide affinity for MHC I allomorphs which are loaded with antigen
in the ER. Less than 1% of all peptides generated via proteasomal degradation bind to
MHC I with the adequate affinity required to stabilize the antigen presentation complex.
For instance, out of 175,000 peptides generated during a pox virus infection, only 150 are
able to bind to MHC I. This phenomenon applies to all organisms, even the extremophile

Methanococcus jannaschii, which shows that the propensity of MHC I to limit the
amount of peptides that bind it is an evolutionarily favoured and ancient event (19).
In addition, proteolytic liberation, TAP transport and TCR recognition are all
steps along the antigen presentation pathway that limit the amount of viral peptides which
eventually elicit detectable CTL responses. The number of antigenic determinants which
are susceptible to and undergo each step steadily decreases from the original pool of viral
peptides (18). Regulatory factors of immunodominance outside the core antigen
presentation mechanism have also been identified, and mouse studies conducted with
vaccinia virus (VV) have shown that the degree of dominance of the immunodominant
determinant is dependent upon the route of immunization (e.g., intraperitoneal vs
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intradermal). This is particularly important for vaccinology because it directly implicates
route of administration as crucial for the generation of a particular CTL response (20).
However, there is a degree of discord between mouse data and the human system,
and CTL responses to VV antigens in humans appear to be more “immunodemocratic”.
In addition, the particular immunodominant determinants recognized in a human cannot
be predicted solely on that person’s HLA genotype, because the CTL repertoire is also
influenced by other HLA allomorphs to which the VV peptides are not restricted (21,22).
Furthermore, humans obviously exhibit greater genetic variability than inbred strains of
laboratory mice, and mutations or substitutions in key elements of the antigen
presentation pathway (i.e., TAPI and TAP2) have been shown to influence the repertoire
of viral peptides which are presented to CTLs (23). Nevertheless, mouse models of
immunodominance remain important tools to study this phenomenon in vivo, because
they can still yield important mechanistic data that can then be evaluated in the human
system.
\

Models o f Immunodominance
Two particularly well studied models of immunodominance other than VV are the
simian vacuolating virus 40 (SV40) large T antigen (TAg) system, and the influenza A
virus (IAV) system. SV40 is a m em ber of the Papovavirdae family of DNA tumour
viruses which came to prominence following the discovery that SV40 could induce
mesothelioma in hamsters. This, combined with the fact that thousands of infants
received an SV40 contaminated polio vaccine during the 1950s-60s, promoted a
significant degree of research into the oncogenic capacity of the virus (24). It was
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subsequently found that the large TAg of SV40 interacts with tumour suppressor genes in
the host cell (i.e., p53) and by deregulating their function promotes oncogenesis. SV40
TAg exhibits four peptides which may elicit measurable CTL responses in the C57BL/6
mouse, and these include Site I, II/III, IV, and V, with IV being the immunodominant
determinant. Site V is sometimes considered immunorecessive because it will only
induce a CTL response in the absence of the other antigenic epitopes (25).
Influenza a virus (IAV) is a prominent human pathogen that induces seasonal
m orbidity in humans on a global scale. In the C57BL/6 mouse, seven M H C I restricted
immunogenic IAV peptides have been identified, and NP 366 and PA 147 are the
immunodominant determinants in that particular system. Many prominent investigators,
including Peter Doherty, utilize the IAV model to delineate the mechanistic details
behind the immunodominance phenomenon. Applying the IAV to study
immunodominance is useful because it is an actual human pathogen, and if administered
intranasally (i.n) in mice also induces morbidity. Therefore using an i.n IAV model can
be used to determine whether any changes in epitope specific CTL responses influence
disease progression or outcome (26-28).

Tryptophan Metabolism and its Effects on the Immune System
Indoleamine 2,3-dioxygenase (IDO) is the endogenous rate limiting enzyme in
tryptophan metabolism, and degrades L-tryptophan (L-Trp) along the L-kynurenine (LKyn) pathway (Figure v). This metabolic route was first described in 1947, but the actual
IDO enzyme was not identified until Osamu Hayaishi’s group accomplished the feat in
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1963, by isolating what was then termed D-tryptophan pyrrolase from the rabbit intestine
(29,30).
IDO is an ancient molecule, one that has been conserved through the last 600
million years o f evolution (31). It is a heme containing cytoplasmic enzyme with two
folding domains, the larger of which (C-domain) is composed of 15 a-helices and
harbours the catalytic pocket. IDO binds L-Trp and promotes the oxidative cleavage of its
pyrrole ring through the insertion of an oxygen molecule or superoxide anion, thus
forming N-formylkynurenine which is then hydroylzed or spontaneously degraded into
other by-products (32).
Unlike tryptophan 2,3-dioxygenase (TDO) which is a housekeeping enzyme
mainly confined to the liver, IDO expression can be induced by immunological stimuli
(e.g., EFN-y) in a variety of tissues and cell types including fibroblasts, epithelial cells,
and vascular smooth muscle cells (33). The Idol gene promoter contains two interferon
stimulated response elements (ISREs), as well as an interferon activated site (GAS),
which induce transcription by responding
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to STAT-1 and IRF-1 signalling (34). Furthermore, in the murine system, IDO is
produced constitutively by select subsets of DCs such as B220+CD19+plasmacytoid and
CD8a+ conventional DCs, and can be induced in other DC types by endogenous stimuli
such as B7-1/B7-2 ligation and TLR-9 signalling, in addition to IFN-y (35,36).
L-Trp is the least abundant essential amino acid, and equates to less than 1% of
the amino acid content in a human being. It is therefore indispensable for the
maintenance o f cellular homeostasis and proliferative capacity in vivo, two processes of
distinct importance for the immune system (29). Due to its potent ability to modulate LTrp levels in the tissue microenvironment, IDO thus exhibits immunosuppressive or
tolerogenic properties and has been implicated as an important factor in maternal fetal
tolerance, allograft survival, rheumatoid arthritis, colitis, and allergy (31,37).

IDO and CD8+ T-cell Function
There are two broad mechanisms through which IDO function mediates immune
suppression, one of which consists of tryptophan starvation, and the other involves the
production o f bioactive tryptophan metabolites (34). Since L-Trp is essential for cellular
proliferation, if it is missing from the tissue microenvironment then resident
immunocytes such as CD8+ T-cells will be unable to expand and execute their functions.
For instance, it has been established that the CTL cell cycle stops at a mid-Gl arrest point
when the cellular microenvironment is devoid of tryptophan (38). In addition, when EDO
expressing DCs interact with CTLs in vivo and in vitro, they induce GCN2 kinase
signalling within the T-cells, thus leading to anergy and proliferative arrest (39). The
GCN2 kinase pathway is activated in response to cellular stress (e.g., L-trp starvation),
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and the proliferative arrest of CTLs in this system was reversed by supplementing the
cells with tryptophan (39). Furthermore, IDO mediated activation of the GCN2 pathway
within tumour draining lymph nodes can block the conversion of FoxP3+T-regulatory
cells into a pro-inflammatory T hl7 like phenotype (40).
It has also been established that L-kynurenine, and its immediate downstream
metabolites like 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and quinolinic acid
exhibit bioactive properties that are in some cases detrimental to immune function (4143). For instance, 3-hydroxyanthranilic acid actually ameliorates morbidity in an
experimental model of asthma, by inducing the apoptosis of T-cells (44). The induction
o f CTL apoptosis by tryptophan metabolites corresponds with caspase-8 activation and
cytochrome C release from mictochondria (45,46). In addition, L-kynurenine and its
metabolites have also been shown to improve cardiac allograft survival in a rat model of
transplantation by suppressing CTL function (47). Furthermore, administration of 3hydroxyanthranilic acid blocks the differentiation of T hl/T hl7 cells and promotes Tregulatory cell function, thus decreasing disease severity in a model of experimental
autoimmune encephalitis (EAE) (48).
IDO has proven to be of particular importance in the field of cancer immunology,
and a steadily expanding volume of literature on the subject attests to this fact. It has been
established that when tumour cells are transfected with IDO, they use its properties to
induce a zone of immunologic privilege surrounding the neoplasm, despite pre-existing T
cell immunity to the cancer (49). In addition, constitutive IDO expression by human
colorectal and ovarian cancer cells is linked to poor clinical prognosis (50,51).
Furthermore, B16F10 tumour cells which constitutively express IDO have been found to
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secure their own growth by inducing T-cell apoptosis in an IDO dependent manner. This
phenomenon can be remedied by treating the tumours with IDO targeting siRNA, which
reduces tumour induced T-cell apoptosis and inhibits cancer growth in vivo (52).
Not only do IDO expressing tumours possess the ability to modulate the immune
system, but IDO+tolerogenic DCs have also been implicated in the development and
maintenance o f cancer. DCs which express IDO have been isolated in the tumour
draining lymph nodes of humans with invasive melanoma, as well as mice with B16
melanoma tumours. Furthermore, IDO+DCs isolated from breast, gastric, and colon
péritumoral regions also express CD25, which adds to their immunosuppressive functions
and helps promote tumour growth (53,54).
In the context of viral infection, IDO and tryptophan metabolism play a more
paradoxical and ill defined role. In one study, the presence of IDO was shown to
potentially benefit patients with dengue virus infection, and the authors claim that the
gamma interferon response to dengue vims is partially dependent on EDO (55). Along
those same lines, IDO has been found to mediate the gamma interferon response to
hepatitis B vims in human hepatocyte derived cells (56). This clearly conflicts with
previously cited literature about the immunosuppressive functions of IDO, but there are
also studies which support a suppressive role for IDO in a viral system. For instance, it
has been established that the absence o f EDO potentiates the type IIFN response to a
murine leukemia vims (LP-BM5), and that EDO KO mice infected with this vims exhibit
a lower viral load and better survival than their wild type counterparts (57).
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Hypothesis and Specific Aims

Clearly the role o f IDO in viral infection remains to be elucidated and thus
represents a field for exciting further research. The purpose of the following study was to
determine the role that IDO plays in epitope specific CD8+ T-cell responses to viral
antigens, and what the functional consequences of this are in vivo. It was hypothesized
that IDO would suppress CD8+ T-cell responses and be detrimental to their cytotoxic
function. The specific aims were 1) to determine the epitope specific CD8+ T-cell
responses to TAg and IAV in EDO KO vs WT mice, 2) to elucidate the mechanistic
details behind this phenomenon (e.g., cross priming, proliferation, anergy, etc.), 3) to
explore the effects of EDO KO on the cytotoxic responses o f epitope specific CTLs and 4)
to illustrate whether IDO KO is protective against disease inducing viral challenge.
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Materials and Methods
Animals
Seven to twelve week old male and female C57B1/6 were purchased from Charles
River Canada and housed in the West Valley Barrier facility at the University of Western
Ontario. Two pairs o f EDO'7' mice were purchased from Jackson Laboratories and a
breeding colony was established at the same West Valley Barrier facility. Mice in control
and experimental groups were always sex matched, aged matched to within + /-1 week of
each other, and moved to the experimental housing room at least three days prior to
treatment, allowing them to acclimatize to the new environment.

Propagation o f PR8 and X31 influenza A virus (IAV)
Embryonated chicken eggs were purchased and placed in an egg incubator at 3335°C. The eggs were then “candled” to determine which had healthy embryos and thus
were suitable for vims inoculation. This was achieved by visualizing each egg in front of
a bright light in a dark room and identifying those with well defined egg sacs and blood
vessel morphology. The healthy eggs were then inoculated with 1:1000 dilution o f PR8
(H1N1) or X31 (H3N2) strain of IAV, by inserting a syringe with a 1 inch needle at a 45
degree angle into the allantoic cavity. One hundred microlitres of vims was injected in
this manner into each egg, which was then returned to the incubator for a further 48
hours. At the completion of the incubation period, the top o f the shell was removed from
the eggs and the allantoic fluid was collected and pooled into 50 ml tubes. This fluid was
then spun down at 400g for 4 minutes and the supernatant was aliquoted into 1 ml glass
tubes for freezing.
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Preparation and intraperitoneal injection oflA V
IAV (H1N1 PR8 and H3N2 X31) virus stock was kept at -80°C in 1 ml aliquots
in PBS. Before injection the virus was thawed and 1 ml o f PBS was added to the aliquot
for a final volume o f 2 mL per tube. Each mouse received 0.5 ml of the diluted virus via
intraperitoneal (i.p) injection, using a 500pl insulin syringe. For experiments focussing
on the acute response, each mouse received a single i.p injection o f PR8 and intracellular
cytokine staining (ICS) was conducted on Day 7. However, if the memory recall response
was to be enumerated, then each mouse received an i.p injection of PR8 on Day 0,
followed by a “booster” i.p injection o f X31 on Day 30. X31 (H3N2) was used instead of
PR8 (H1N1) in order to avoid a neutralizing antibody response against the second viral
challenge. The ICS was then conducted on Day 37.

Preparation and intranasal innoculation oflA V
A final pfu of 6-8 pfu per mouse was prepared by serial dilutions of PR8 virus
stock in PBS. Mice were anesthetised with a 70:30 ratio of isofluorane and propylene
glycol, and were considered properly subdued when the toe pinch reflex was absent. A
total o f 50 pi o f PR8 virus solution was pipetted into the nose o f each animal, which
corresponded to 6-8 pfu per mouse in each experiment. Each mouse was kept in an
upright position, for at least a minute following inoculation, to ensure that the virus did
not leak back out o f the nostrils or mouth. The animals were then weighed each day to
monitor their infection and health status.
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Preparation and intraveritoneal injection o f C57SV and KD2SV cells
C57SV cells are a transformed fibroblast cell line from C57B1/6 mice that also
stably express the large T antigen (TAg) of SV40 virus (58). When injected into C57B1/6
mice, C57SV cells induce MHC I restricted CD8+T-cell responses to TAg. KD2SV cells
express TAg as well, but this is a kidney epithelial cell line from BALB/c mice and thus
exhibits a different MHC haplotype: H2d. When injected into C57B1/6 mice, KD2SV
cells promote T-cell responses against TAg, but also induce an alloreactive response due
to the MHC incompatibility (59).
Regardless of cell line, on Day 0 mice were injected intraperitoneally with 20x106
cells using a 1 ml insulin syringe. The cells were cultured prior to injection in DMEM
medium with 10% fetal calf serum (FCS) and no antibiotics. The desired pre-injection
confluence of 90-100% was achieved by seeding 2.0x106 cells in a 175cm3 culture flask
for three days.

l-Methyl-D-Tryptophan (1-MT) preparation and intraoeritoneal injection
1-MT was purchased from Sigma in several different batches. Twenty five
milligrams of 1-MT was dissolved in 2 ml of 0.1 M NaOH. The solution was brought up
to a neutral pH by drop wise addition of 12 M HCL and then filtered through a syringe
top filter after addition of 2.98 mL of PBS. Thus, the final concentration of 1-MT in the
pH adjusted solution was 5mg/ml. The control solution consisted of an ion matched PBS
preparation (155mM NaCl). Each mouse was treated with 0.5 ml of 1-MT solution via
the i.p route, which equates to 2.5 mg of 1-MT, per day for two days prior and two days
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following C57SV injection. Age and sex matched controls received the same volume of
vehicle over the same injection schedule.

L-Kvnurenine (L-Kvn) preparation and intraoeritoneal injection
L-Kyn was purchased from Sigma. Fifty milligrams of L-Kyn was dissolved in 5
ml of PBS in order to produce a solution with a concentration of lOmg/ml. Each mouse
received lOmg of L-Kyn in 1 ml injections on the day of and two days following C57SV
or IAV injection. Control mice received 1ml of PBS as vehicle in 1ml injections over the
same schedule.

Intracellular cytokine staining (ICS)
Mice were euthanized via cervical dislocation on either Day 7 (IAV) or Day 9
(C57SV) post injection. Following retraction of the skin on the abdominal region,
peritoneal exudates cells (PECs) were collected by flushing the inside of the peritoneal
cavity with 10 ml of PBS; a 10 ml syringe attached to a 19 gauge needle was used to
achieve this. The spleen from each animal was then excised and disrupted with a glass
homogenizer. After centrifugation at 400 ref for 4 minutes, the pelleted homogenates
were subjected to ACK lysis buffer, thus removing most red blood cells from the
suspension.
Rotational filtration was then employed to clear the fat and other organ debris
from the homogenates. This entailed slowly decanting each suspension into a clean 15ml
falcon tube, whilst rotating to ensure that fat remained on the walls of the parent tube.
These splenocytes were counted using a haemocytometer and the volume of the
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suspensions was adjusted to a final concentration of 20 x 106 cells per ml in 1 ml of
complete RPMI (cRPMI) medium.
Synthetic peptides corresponding to the antigenic determinants of IAV or TAg
were prepared at 1pM concentrations in 2 ml of cRPMI medium. A medium only control
was also prepared, as well as a control using an irrelevant peptide. In all cases the
irrelevant peptide was GB 498 because it exhibits the appropriate M H C I restriction and is
also the most immunodominant epitope in the HSV-1 system. C57SV cells and a DC2.4
cell line infected with IAV were used to enumerate the overall T-cell response to all
antigenic epitopes of either TAg or IAV, and functioned as a positive control.
The splenocytes were plated on a non-tissue culture treated 96 well plate, with
2.0x106 splenocytes per well. One hundred microlitres of the synthetic peptides and
controls were then added to the appropriate wells, thus ensuring a final volume of 200 pi
per well. The plate was incubated for 2 hours at 37°C and 6% CO 2. At the end of 2 hours,
20 pi of O.lmg/ml Brefeldin A was added to each well in order to attenuate protein
secretion and thus retain any synthesized cytokines inside the cell. The plate was then
incubated under the same conditions for a further 3 hours.
At the 3 hour interval, the plate was centrifuged at 2100 rpm for 5 minutes at 4°C.
Following removal of the supernatant and a quick vortex to disrupt the pellets, Fc block
(2.4G2 hybridoma supernatant) was added to the wells and the plate was incubated on ice
for 15 minutes. An anti-mouse CD8 monoclonal antibody conjugated to allophycocyanin
(APC) was then added to each well and incubated in the dark on ice for a further 30
minutes. Following three washes with PBS and PBS with 0.5% bovine serum albumin
(BSA), the cells were fixed for 20 minutes using 1% paraformaldehyde at room
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temperature. A solution containing 1% saponin, PBS and an anti-mouse IFN-y
monoclonal antibody conjugated to fluorescein (FITC) was prepared and then added to
each well after two washes with PBS and PBS+0.5%BSA. The plate was sealed with
parafilm and incubated at 4°C overnight. The next morning the wells were washed with
PBS and PBS 0.5% BSA, brought up to a final volume of 200 pi in PBS BSA, and
enumerated via flow cytometric analysis.

Synthetic peptides used for ICS
The synthetic peptides used for splenocyte restimulation were provided by Dr.
Jonathan Yewdell’s lab at the NIH in Bethesda, Maryland. Stock solutions were prepared
at a concentration of ImM in DMSO and stored at -30°C. See Figure vi for details.

Figure vi - Synthetic Peptides from SV40 and IAV

IAV PR8 Peptides + M H C Restriction
Er
IAV NP224-233
Db
IAV PA 366-374
Kb
IAV PB I 703-711
Db
IAV PB1-F262.70
Kb
IAV M l 128-135
IAV NS2H4-121 Kb
IAV PB2

SY40 TAg Peptides + M H C Restriction
Db
SV40 Site I: TAg 206-2i5
SV40 Site II/III: TAg223-23i Db
Kb
SV40 Site IV: TAg404-4ii
Db
SV40 Site V: TAg 498_497
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Staining for Intracellular and Extracellular Markers
Splenocytes were prepared, plated, and restimulated with peptides as described
above in the ICS section. However, in addition to using anti-mouse CD8-APC and anti
mouse IFN-y-FITC antibodies, the following antibodies were also included as
appropriate: anti-human Ki67-FITC, anti-mouse programmed death one (PDl)-PE, anti
mouse CHOP-FITC, anti-mouse IFN- y-PE. All of these additional antibodies were
prepared using a standard 1:100 dilution. Ki67-FITC and CHOP-FITC are intracellular
markers and so were added in conjunction with IFN-y-PE in parallel wells. PD1-PE is
extracellular and was included with the CD8-APC antibody cocktail.

Tetramer Staining

Site IV-PE and Site I-APC tetramers were acquired from Todd Schell at the Penn
State. Splenocytes from C57SV challenged mice were prepared as described in the ICS
section, and 1.Ox 106 cells were transferred to two tubes for tetramer staining. The cells
were spun down at 400 ref for 4 minutes and Fc blocked for 10 minutes on ice. The
respective tetramer cocktails were prepared using a 1:100 dilution in PBS+0.5%BSA, and
a 1:100 dilution of anti-mouse CD8-FITC antibody was included in the mix (e.g., Site
IV-PE + CD8-FITC). These tetramer cocktails were then added to the appropriate tube
for 15 minutes at room temperature, and then the cells were washed, fixed with 1.0%
paraformaldehyde, and enumerated using flow cytometry.
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In vivo killins assay (IKA)
Naive C57B1/6 mice were sacrificed via cervical dislocation and their spleens
were excised and processed as described in the ICS section. The splenocytes were then
partitioned into two tubes and pulsed with either Site IV peptide or the GB 498 irrelevant
peptide at luM concentrations. These suspensions were incubated for 45 minutes at 37°C
and 6% CO 2, and then washed twice with PBS.
The two splenocyte pools, pulsed with Site IV and GB 498, were then labelled with
a high (5pM) and a low (1.5 pM) concentration of CFSE dye respectively, so that they
could be distinguished later by flow cytometry. After the dye was added at the
appropriate concentration, the cells were incubated for 20 minutes at 37°C and 6% CO 2,
then washed, counted, equalized, and mixed into one tube (a count of 4 x l0 6 cells in each
group was the minimum acceptable number, for a total of at least 8xl06 cells total).
The mixed splenocyte pool was then injected intravenously into mice that had
been treated with C57SV cells nine days previously, as well as two naive control mice.
All mice were warmed under infrared light for at least an hour before injection to ensure
adequate vasodilation, and the tail was dipped in warm water immediately prior to
injection. A 500pl syringe with a 27 gauge needle was used to inject 200pl of the cell
suspension into each mouse. Instantly following the injection of each mouse, a timer was
started for 45 minutes, the time corresponding to the desired in vivo killing time in the
animals.
The recipient mice were euthanized via cervical dislocation at the 45 minute time
point in the same order they were injected, to ensure that each animal experienced the
same in vivo killing time. Their spleens were excised and processed in the manner
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discussed in the ICS section, and then immediately enumerated via flow cytometric
analysis. All steps were conducted in the dark to ensure the preservation of the CFSE dye
in the cell suspension.

Flow Cytometry
Events were acquired using a BD FACS Canto II machine in conjunction with BD
FACS Diva software. Analysis was performed using Flow Jo software. When required,
compensation libraries were prepared with single stained splenocytes using the BD FACS
Diva software options.

Statistical analysis
The data was analysed in most cases using the Student’s t test in Microsoft Excel 2007. P
values less than 0.05 were considered significant (* <0.05, ** < 0.01, *** < 0.001)
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Results

IDO suppresses CD8+ T-cell responses to the immunodominant epitopes of SV40 TAs
and IAV
IDO has already been shown to suppress T-cell activity in a variety of contexts
(39), but its effect on epitope specific CTL responses to viral antigens has not been
investigated. To that end, three separate ICS experiments in IDO KO and WT mice
treated with C57SV cells i.p, showed that the absence of IDO increased the percentage
and absolute number of IFN-y+ CD8+ T-cells specific for the immunodominant site IV
epitope of TAg. This cell population corresponds to CTLs that were activated in vivo and
secreted IFN-y upon re-stimulation with synthetic peptides ex vivo. In addition, IDO KO
did not affect CTL responsiveness to the other antigenic determinants, but did increase
activity against C57SV cells ex vivo, a response that is largely driven by the site IV
epitope itself (Figure 1). These results suggest that IDO exhibits an apparently selective
CTL inhibition, whereby it only affects the T-cells responding to the most
immunodominant epitope of TAg.
A similar phenomenon was seen in mice treated i.p with KD2SV cells, and two
ICS experiments again enumerated a statistically significant difference in the percentage
and absolute number of activated CD8+ T-cells specific for the site IV epitope (Figure 2).
This confirmed the observation was not limited to treatment with one cell type, and also
implicated cross priming as a possible mechanistic detail in the process. Since KD2SV
cells express an H2d MHC restriction, any CTL responses to TAg in a C57B1/6 mouse
must have been driven by cross priming via endogenous DCs. C57B1/6 T-cells would not
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Figure 1 - Epitope specific T-cell responses to C57SV in IDO KO vs WT mice

Mice were injected with C57SV cells i.p and ICS for IFN-y was conducted on splenocytes on Day 9
following injection. The figure shows A) the percentage of IFN-y+CD8+T-cells specific forTAg
epitopes in IDO KO vs WT mice and B) the absolute number of IFN-y+CD8+T-cells specific forTAg
epitopes in IDO KO vs WT mice; numbers calculated based on bulk splenocyte count. Data from
pooled experiments: INI = 12 WT & 10 IDO KO
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Figure 2 - Epitope specific T-cell responses to KD2SV in IDO KO vs WT mice

Mice were injected with KD2SV cells i.p and ICS for IFN-y was conducted on splenocytes on Day 9
following injection. The figure shows A) the percentage of IFN-y+CD8+T-cells specific forTAg
epitopes in IDO KO vs WT mice and B) the absolute number of IFN-y+CD8+T-cells specific forTAg
epitopes in IDO KO vs WT mice; numbers calculated based on bulk splenocyte count. Data from
pooled experiments: N = 8 WT & 8 IDO KO
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have been able to directly recognize TAg epitopes presented in the context of H2d MHC
molecules and thus would have had to rely on host DCs to present the antigenic material.
It is possible that the difference in CTL responsiveness between IDO KO and WT
mice was due to an intrinsic T-cell phenotype or repertoire defect in the knockout mice
themselves. To address these concerns, WT mice were treated with either 2.5 mg/day of
1-MT (a competitive inhibitor of the IDO enzyme) or vehicle for two days prior and post
C57SV injection, and the ICS was again conducted as described. The results of these 3
experiments exactly paralleled those seen in the knockout studies, and mice treated with
1-MT exhibited a higher percentage and absolute number of T-cells specific for site IV of
TAg (Figure 3). This shows that the results are replicable in WT mice treated with an
IDO inhibitor, and ascribes a causational role for the IDO enzyme in this system, while
eliminating the possibility of confounding variables in the knockout mice themselves.
The use of 1-MT was then validated by excluding the possibility of any potential
off target effects of the inhibitor itself. This was accomplished by treating WT and IDO
KO mice with either 1-MT or vehicle, and enumerating activated CTL frequency via ICS.
Though an increase was observed in the 1-MT treated WT mice when compared with
vehicle treated controls, no concomitant increase was detected between the IDO KO
groups, suggesting that 1-MT is indeed specific to the IDO enzyme (data not shown).
In order to determine whether these finding were applicable to other model
systems, the same ICS experiments were performed using IDO KO and WT mice treated
with i.p. IAV. Again, the results of these investigations show that in the absence of EDO,
the animals developed a more robust CTL response (both percentage and absolute
number) to the two immunodominant epitopes (NP and PA) of IAV in both a primary and
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Figure 3 - Epitope specific T-cell responses to C57SV in 1-MT treated vs PBS treated mice

Mice were injected with 2.5mg/day of 1-MT for 2 days prior and 2 days post C57SV injection. ICS for
IFN-y was conducted on splenocytes on Day 9 following cell injection. The figure shows A) the
percentage of IFN-y+CD8+T-cells specific forTAg epitopes in IDO KO vs WT mice and B) the absolute
number of IFN-y+CD8+T-cells specific for TAg epitopes in IDO KO vs WT mice; numbers calculated
based on bulk splenocyte count. Data from pooled experiments: N = 7 PBS & 7 1-MT
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Figure 4 - Epitope specific primary T-cell responses to IAV in IDO KO and WT mice

Mice were injected with IAV i.p, and ICS for IFN-y was conducted on splenocytes on Day 7 following
injection. The figure shows A) the percentage of IFN-y+CD8+T-cells specific for IAV epitopes in ID0
KO vs WT mice and B) the absolute number of IFN-y+CD8+T-cells specific for IAV epitopes in IDO KO
vs WT mice; numbers calculated based on bulk splenocyte count.
Data from pooled experiments: N = 11 WT & 11 IDO KO
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Figure 5 - Epitope specific memory T-cell responses to IAV in IDO KO and WT mice

Mice were injected with IAV (PR8) i.p on Day 0 and IAV (X31) i.p on Day 7. ICS for IFN-y was
conducted on splenocytes on Day 30. The figure shows A) the percentage of IFN-y+CD8+T-cells
specific for IAV epitopes in IDO KO vs WT mice and B) the absolute number of IFN-y+CD8+T-cells
specific for IAV epitopes in IDO KO vs WT mice; numbers calculated based on bulk splenocyte count.
Data from pooled experiments: N = 8 WT & 8 IDO KO
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memory recall context (Figure 4 and 5). This is important because it illuminates a more
general role for IDO in the modulation of CTL responses to viral antigens, and that the
phenomenon is not only confined to one model system.
Intracellular cytokine staining is a versatile experimental modality, because it also
allows the enumeration of cytokine production on a per cell basis via mean fluorescence
intensity (MFI). In this case, in both the TAg and IAV systems, even though IDO KO
mice had a higher percentage and number of IFN-y+CD8+ T-cells specific the
immunodominant epitope following i.p treatment with C57SV cells or IAV, there was no
difference in IFN-y production on a per cell basis (Figure 6). This means that in the
absence of IDO, there exists a higher frequency of activated immunodominant T-cells,
but the individual IDO KO cells do not become more highly activated than WT cells.
Collectively, these experiments show that there is an increased number of
activated immunodominant CTLs when IDO is absent, which seems to implicate a
proliferative phenomenon as the mechanistic mediator behind these results. This can be
logically reconciled with the purported function of IDO, which is to inhibit the
proliferation of T-cells through localized tryptophan deprivation and/or the production of
toxic, tryptophan derived metabolites. It is thus possible that in the steady state, site IV
specific CTLs proliferate more than their sub dominant counterparts, due to their singular
nature as immunodominant responders. In the absence of EDO, these highly proliferating
immunodominant CTLs are able to expand to an even higher degree, because they are
more sensitive than subdominant T cell clones to tryptophan degradation and
microenvironment toxicity when IDO is present.
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Figure 6 - Mean fluorescence intensity of IFN-y in epitope specific T-cells (C57SV and IAV) in IDO
KO vs WT mice

Mean fluorescence intensity is a measure of IFN-y production on a per cell basis. A) MFI of IFN-y in
IFN-y+CD8+T-cells specific for TAg epitopes in IDO KO vs WT mice and B) MFI of IFN-y in IFN-y+CD8+
T-cells specific for IAV epitopes in IDO KO vs WT mice. Data from pooled experiments: TAg N = 12
WT & 10 IDO KO, IAV N = 11 WT & 11 IDO KO
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In order to address this hypothesis, it therefore became important to question
whether treating mice with L-kynurenine, the most immediate stable downstream
metabolite of L-tryptophan, would in fact suppress site IV specific T-cell responses in
WT mice. This would show whether immunodominant CTLs are more sensitive to
tryptophan metabolites than subdominant clones.

Treatment of mice with L-kvnurenine does not suppress specific T cell responses to TAs
orlAV
It is well established in the literature that L-kynurenine and its downstream
metabolites exhibit immunosuppressive properties in vivo (42,60,61). This is why the
generation of toxic metabolites is considered one of the mechanisms through which EDO
modulates immune function.
Given the hypothesis that immunodominant CTLs are more sensitive to the toxic
microenvironment created by tryptophan catabolism, WT mice were treated with i.p Lkynurenine and C57SV cells. The subsequent ICS experiments yielded surprising results,
because they recapitulated the same trend seen in the IDO KO and inhibition
experiments: an increase in the frequency of IFN-y+CD8+ T-cells specific for site IV
(Figure 7). In addition, there was an L-kynurenine dose dependent increase in the
frequency of site IV specific cells (Figure 8). This was contrary to all expectations in the
published literature, and may speak to some putative negative feedback loop through
which high concentrations of L-kynurenine actually inhibit IDO. This however is all
speculative and based upon a similar phenomenon with TDO, a housekeeping enzyme in
the liver that also degrades tryptophan (62,63).
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Figure 7 - Epitope specific T-cells responses to C57SV cells in L-Kyn treated vs PBS treated mice

Mice were injected i.p with either vehicle or lOmg/day of L-Kyn on the day of, and two days
following C57SV i.p injection. ICS was conducted on splenocytes on Day 9 post injection and the
figure shows A) the percentage of IFN-y+CD8+T-cells specific forTAg epitopes in L-Kyn vs PBS
treated mice and B) the absolute number of IFN-y+CD8+T-cells specific for TAg epitopes in L-Kyn vs
PBS treated mice. Data from pooled experiments: N = 8 PBS & 8 L-Kyn
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Figure 8 - Epitope specific T-cells responses to C57SV cells in mice treated with different doses of
L-Kyn vs PBS treated mice

Mice were injected with either vehicle or 5mg/day or lOmg/day of L-Kyn on the day of and two days
after C57SV injection. The figure shows the percentage of IFN-y+CD8+T-cells specific forTAg
epitopes in L-Kyn vs PBS treated mice. N = 4 PBS & 2 L-Kyn 5 mg & 2 L-Kyn 10 mg
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Figure 9 - Epitope specific T-cells responses to IAV in L-Kyn treated vs PBS treated mice

Mice were injected with either vehicle or lOmg/day of L-kyn on the day of and two days after IAV
injection. The ICS was conducted on Day 7 post injection and the figure shows the percentage of
IFN-y+CD8+T-cells specific for IAV epitopes in L-Kyn vs PBS treated mice. N = 4 PBS & 4 L-Kyn
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Since the results of the L-Kyn TAg experiments were relatively unexpected and
controversial, they were repeated in the IAV system where a similar trend was observed
(Figure 9). Although it would be inappropriate to unreservedly claim L-kynurenine
treatment actually increased CTL responses (because the data did not reach statistical
significance), it is safe to conclude that the tryptophan metabolite did not suppress them.
Taking these results into account, the hypothesis was augmented accordingly: IDO
inhibits the responsiveness of immunodominant CTLs by suppressing their proliferation,
but does so in an L-kynurenine independent manner.
With the role of tryptophan metabolites in this system illuminated, it was thus of
importance to elucidate whether the absence of IDO actually affects the proliferative
capacity of immundominant and subdominant CTLs, as the previous ICS data seemed to
suggest.

IDO suvresses the proliferative capacity o f activated epitope specific CTLs
In order to determine whether activated CTLs specific for the site IV epitope
proliferated more robustly in the IDO KO condition than WT, the ICS protocol was
modified to include markers of proliferation (Ki67) and anergy (PD1 and CHOP). The
classic CD8 and DFN-y antibodies were used as before to identify activated epitope
specific CTLs, whilst Ki67, PD1, and CHOP provided insight into the proliferative
mechanisms involved in this phenomenon.
The main cell population of interest was the CD8+ pool that also expressed EFN-y
and Ki67. These cells represented epitope specific (either site IV or site I) CTLs that
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were actively proliferating in vivo at the time of euthanasia (64). In accordance with the
hypothesis, IDO KO mice exhibited a higher percentage of IFN-y+Ki67+CTLs specific
for site IV when compared with WT mice on Day 9 following i.p injection of C57SV
cells. The same was true for site I specific CTLs, but the increase in frequency between
KO and WT was much smaller than for the immunodominant clones (Figure 10 and 11).
This means that these activated cells were proliferating more robustly in the absence of
IDO, and explains why there was a higher frequency of activated immunodominant CTLs
in EDO KO animals in the previous experiments. Site IV IDO KO CTLs also expressed
more Ki67 on a per cell basis than their WT counterparts, as seen via MFI (Figure 12).
In addition, there was a higher frequency of PD1+IFN-y+ Site IV specific CTLs in
IDO KO animals, and though PD 1 is a marker of anergy, it has been reported that highly
proliferating cells express higher levels of this cell surface molecule (Figure 13) (65). By
taking this finding into account, and combining it with the Ki67 expression data, it
becomes clear that IDO suppresses the proliferation of activated immunodominant CTLs

in vivo.
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Figure 10 - Percentage of Ki67+ IFN-y+ CD8+ T-cells specific for Site I and Site IV in IDO KO vs WT
mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for marker staining. Data representative of two experiments: N= 7 WT & 7 IDO KO
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WT
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IFN-y
Figure 11 - Flow cytometry plots showing Ki67 and IFN-y expression in a CD8+T-cell population
specific for either Site IV (top panel) or Site I (bottom panel)
Flow cytometry gating strategy for Ki67 expression. Data representative of two experiments: N= 7
WT & 7 IDO KO
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Figure 12 - Mean fluorescence intensity of Ki67 in IFN-y+CD8+ CTLS specific for either Site I or Site
IV in IDO KO vs WT mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for marker staining. MFI is a measure of Ki67 production on a per cell basis. Data
representative of two experiments: N= 7 WT & 7 IDO KO
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CHOP is a product of GCN2 kinase signalling, and has been used as a reporter
protein for IDO function (39). Previous studies showed that EDO producing DCs induce
GCN2 kinase activity (as measured by CHOP production) in T-cells, which in turn
become anergic or upregulate their suppressor functions. Therefore it was of mechanistic
interest to determine whether there was a difference in frequency of activated CHOP+
immunodominant CTLs in IDO KO vs WT mice. The hypothesis was that a lower
proportion of IDO KO CTLs would express CHOP, because there would be no IDO in
the system to induce GCN2 kinase signalling. This would also have implicated GCN2
kinase as one of the factors behind IDO mediated suppression of immunodominant CTLs
in WT mice. However, following completion of two experiments (i.p injection of C57SV
cells and marker staining on Day 9 post injection), IDO KO and WT animals exhibited no
differences in the frequency of activated site IV or site I CTLs that were also CHOP
positive (Figure 14). These results indicate that GCN2 kinase signalling is not responsible
for the differences in CTL frequency between IDO KO and WT mice in the TAg system.
This modified ICS approach also provided insight into whether there was any
proliferative difference between immunodominant and subdominant CTLs in WT mice,
and if the non-activated CD8+IFN-y cells also varied in proliferative capacity between
IDO KO and WT animals. It was found that WT IFN-y+ site IV specific cells exhibited
increased Ki67 expression than their site I counterparts, adding credence to the assertion
that immunodominant cells proliferate more robustly than subdominant clones (data not
shown). In addition, there was no difference in the IFN-y' Ki67+ CTL frequency in IDO
KO vs WT mice, suggesting that IDO only affects the proliferation of activated cells
(Figure 15).
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Figure 13 - Percentage of P D l+IFN-y+CD8+ T-cells specific for Site I and Site IV in IDO KO vs WT
mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for marker staining. Data representative of two experiments: N= 7 WT & 7 IDO KO
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F r e q u e n c y of C H O P
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Large T Antigen Epitopes

Figure 14 - Percentage of CHOP+IFN-y+CD8+ T-cells specific for Site I and Site IV in IDO KO vs WT
mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for marker staining. Data representative of two experiments: N= 7 WT & 7 IDO KO
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Based on these results, it was logical to conclude that EDO suppresses the
proliferation of activated immunodominant CTLs in an L-kynurenine and CHOP
independent manner, thus modulating the frequency of these cells in vivo. However, in
order to further this assertion it became necessary to determine whether IDO also affects
the frequency of cells with the specific site IV or site ITC R , regardless of activation
state.

IDO does not affect the frequency o fT cell clones with the site IV or site I specific TCR

The experiments up to this point have focussed on CD8+ T-cells that produce
IFN-y when re-stimulated by synthetic peptides that equate with specific epitopes of TAg
or IAV. This cell population corresponds to activated CTLs that recognize the antigenic
determinant in question (e.g., site IV), but does not include all of the clones with the
appropriate epitope specific TCR. There are also cells with the correct TCR that were not
activated in vivo and thus do not respond to peptide re-stimulation. In order to adequately
evaluate whether IDO only affects the frequency of activated CTLs, it was thus necessary
to determine its effects on the entire pool of clones, regardless of their activation state.
Through the use of tetramer staining on splenocytes extracted on Day 9 post
C57SV injection, it was determined that IDO does not affect the frequency of CTLs with
either the site IV or site I TCR (Figure 16). There was no significant difference in the
percentage of site IV tetramer+CD8+ cells between IDO KO and WT mice. This was
consistent with the hypothesis that IDO only suppresses clones that are activated in vivo,
which was suggested by the ICS and proliferation marker data.
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Figure 15 - Percentage of Ki67+IFN-y'CD8+ T-cells specific for Site I and Site IV in IDO KO vs WT
mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for marker staining. Figure shows the percentage of Ki67+ non-activated (IFN-y ) CTLs in
IDO KO vs WT mice. Data representative of two experiments: N= 7 WT & 7 IDO KO
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Figure 16 - Percentage of Tetramer+CD8+ T-cells specific for Site I and Site IV in IDO KO vs WT mice

Mice were injected with C57SV cells i.p on Day 0 and splenocytes were extracted on Day 9 post
injection for tetramer staining. Data from pooled experiments: N = 5 WT & 5 IDO KO
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Taking all of the experimental results into account, it is possible to conclude that
IDO decreases the frequency of activated immunodominant CTLs, by reducing their
proliferative capacity in vivo, and that it does not simultaneously affect non-activated Tcell clones. This makes inherent sense because non-activated T-cell clones would not
necessarily be proliferating above homeostatic levels (66), and thus the presence or
absence of the IDO enzyme should not affect the frequency of these cells.

IDO moderately suppresses evitove specific CTL cytotoxicity

Though ICS for IFN-y is a CTL functional assay, it does not allow for the
enumeration of actual CTL killing capacity. The ability of CTLs to kill virally infected
cells is particularly important to ameliorate infection and limit morbidity in a variety of
different contexts (67,68). Thus, it was crucial to determine whether the EDO KO
mediated increase in immunodominant CTL frequency, actually has salient clinical
implications, by measuring its affect on CTL cytotoxicity.
After the completion of three in vivo killing assays, during which EDO KO and WT mice
were injected with C57SV cells and then re-challenged nine days later with syngeneic,
site IV or control peptide pulsed splenocytes, it was determined that the absence of IDO
induces a moderate, yet statistically significant increase, in the cytotoxicity of site IV
specific CTLs (Figure 17). Though the increase in killing was relatively small, it can be
argued that the induction of a 5% higher rate of cytotoxicity by knocking out one enzyme
is still important. In a therapeutic context, an EDO inhibitor could be used in conjunction
with other pharmaceutical approaches to further augment CTL responses.
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Figure 17 - Cytotoxicity of IDO KO vs WT CTLs specific for Site IV

Mice were injected with C57SV cells i.p on Day 0, and on Day 9 re-challenged i.v. with CFSE labelled
syngeneic splenocytes pulsed with either Site IV or control peptide. Killing was allowed to occur for
30 minutes in vivo at which point the mice were sacrificed. The figure shows % specific killing of Site
IV peptide pulsed C57BI/6 splenocytes by CTLs in IDO KO vs WT mice
Data from pooled experiments: N = 6 WT and 6 IDO KO
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Due to the small but statistically significant increase in CTL killing, it became
important to put these findings into a more physiological perspective and determine
whether the results were biologically relevant. To accomplish this objective, the role of
EDO was elucidated in an actual disease model of IAV.

IDO does not affect morbidity in an intranasal model oflAV infection
Since intraperitoneal IAV injection fails to induce an active disease state in mice,
it became necessary to devise a model of infection that produces detectable morbidity.
This would serve to elucidate whether the ICS findings in the i.p systems were applicable
to other modes of infection, and if the increase in both the frequency and cytotoxicity of
immunodominant CTLs translated to better protection against disease.
Animals treated with 6-8 pfu of IAV intranasally began losing weight between 57 days following inoculation, and the ICS was then conducted on day 9 or when the mice
had lost 20% of their body weight. It was hypothesized that mice lacking the IDO
enzyme would be better protected against IAV insult, due to the higher frequency of
immunodominant CTLs and the slightly improved cytotoxic capacity of these cells.
After the conclusion of two experiments, it became apparent that IDO KO mice
lost the same amount of weight as WT mice, at about the same time (Figure 18). IDO KO
mice did, however, exhibit a trend toward increased frequency of immunodominant CTLs
in the spleen, which was consistent with the results from the i.p systems (Figure 19).
Thus, even though IDO suppresses the frequency of epitope specific CTLs as well as
their killing capacity, it does not seem to affect an animal’s susceptibility to disease at
least in an acute context. However, it is possible that the EDO KO mice would have

53

recovered more quickly than WT mice from IAV infection, had the experimental time
course been adjusted to study this phenomenon. In addition, EDO KO mice may have
been better protected against a higher dose of IAV following an initial vaccination with
the vims.
It was also interesting to conduct ICS on the cells collected via bronchoalveolar
lavage (BAL), since these were the in situ responding cells in the lungs and would be
directly responsible for killing virally infected host cells. IDO KO and WT mice
exhibited a similar frequency of epitope specific CTLs in the BAL fluid, and this might
speak to why IDO KO mice were not better protected from acute IAV infection (Figure
20). It is possible that the presence or absence of IDO has differential effects on CTL
responses, depending on whether the response is local (BAL) or systemic (spleen).
In addition, there appeared to be a modified immunodominance hierarchy in the
lung. The subdominant epitopes induced a much higher CTL response than in the spleen,
and the levels were on par with the immunodominant peptides. This was a side
observation but none the less a potentially important one, because such a phenomenon
has never been reported before.
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Figure 18 - Percent weight loss in i.n IAV challenge IDO KO and WT mice

Mice were challenged with 6-8 pfu of IAV i.n on Day 0 and health status (weight loss) was
monitored on a daily basis with a digital scale. The figure shows A) percent weight loss in
Experiment 1: N = 3 WT & 3 IDO KO, and B) percent weight loss in Experiment 2: N = 3 WT & 3 IDO
KO
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S p l e n i c C D 8 + T-C e ll R e s p o n s e s to I A V

Splenic CD8+ T-Cell Responses to IAV

IAV Epitopes

Figure 19 - Splenic epitope specific T-cell responses to i.n IAV in IDO KO vs WT mice

Mice were challenged with 6-8 pfu of IAV i.n on D ay 0 and ICS was conducted on splenocytes on Day
9 post injection. The figure shows A) the percentage and B) the absolute number of IFN-y+CD8+Tcells specific for IAV epitopes. Data representative of two experiments: N = 6 WT & 6 IDO KO
56

B A L T-cell R e s p o n s e s to I A V E p i t o p e s

IAV Epitopes

Figure 20 - Bronchoalveolar lavage (BAL) T-cell responses to i.n IAV in IDO KO vs WT mice

Mice were challenged with 6-8 pfu of IAV i.n on Day 0 and ICS was conducted on BAL lymphocytes
on Day 9 post injection. Figure shows the percentage of IFN-y+CD8+T-cells specific for IAV epitopes
Data representative of two experiments. BAL cells pooled from 3 WT and 3 IDO KO mice
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Discussion
The data detailed in this thesis clearly show that IDO plays a role in the negative
regulation of epitope specific T-cell responses to viral antigens. This effect is mediated
by the decreased proliferative capacity of activated immunodominant CTLs when IDO is
present, and also translates to less efficacious cytotoxic functions of these cells. This
phenomenon occurs in an L-kynurenine independent manner, and therefore must be
primarily mediated by the absence of tryptophan in the cellular microenvironment.
Though IDO does not affect morbidity or survival in mice infected with i.n IAV in an
acute context, it is still likely that it would modulate disease progression and/or recovery
from illness in a vaccination challenge model, since IDO also suppresses the generation
of memory recall responses in vivo.
The finding that IDO primarily affects the most immunodominant CTLs is an
important one, because it highlights a previously unappreciated mechanism of EDO
mediated immune regulation. Given the increased propensity of immunodominant CTLs
to proliferate, it makes sense that these cells would be most sensitive to changes in
microenvironment tryptophan levels. In fact, this was one of my earliest hypotheses, and
it was derived from the published observation that CTLs and certain pathogens require
different levels of tryptophan to function; the data was used to explain why IDO is
considered to be immuno-suppressive, but also paradoxically linked to microbial defence
(69,70). Thus, though inhibiting or knocking out IDO does not alter the
immunodominance hierarchy (i.e., increasing Site II/III responses) it still provides an
avenue for the control and/or enhancement of immunodominant CTL function. This
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provides some rationale to investigate the use of IDO inhibitors to help combat viral
infection and disease progression in hosts of varied immuno-competence status.
In addition, given the published contradictory role that EDO plays in viral
infection (i.e., positive in some contexts and negative in others) it was important to utilize
a variety of model systems to ensure that the results were applicable in more than one
context. The above study employed several different approaches (e.g., i.p TAg, i.p IAV
acute and memory, i.n IAV) to arrive at the same conclusion, which adds credence to the
findings amid the often paradoxical results in different publications. Importantly, the i.n
IAV system was an actual disease model, which allows for the comparison of these
results with published literature in other viral infections such as dengue and HCV. In the
case of dengue, although EDO was actually shown to be beneficial in combating
morbidity in one study, the particular nature of dengue vims infection (e.g., the fact that it
infects DCs) may perhaps explain why IDO is beneficial in this case (55).
Another interesting result was that L-kynurenine and its metabolites did not affect
CTL responses to viral antigens. Most literature on the subject states that tryptophan
catabolites exude immunosuppressive functions in vivo (32,38,42,46,47), but in the
systems studied here they had no effect. In fact, the data seems to suggest that treating
mice with L-kynurenine actually improves the CTL response, although given the
controversial nature of this conclusion, more experimentation is needed to solidify the
results beyond any reasonable doubt. In any event, it is possible that high concentrations
of tryptophan metabolites actually inhibit IDO in a negative feedback loop, although no
studies have ever identified such a mechanism. There is, however, precedent for such a
phenomenon with TDO, which is the housekeeping enzyme in the liver, because its
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function is inhibited by nicotinic acid derivatives, which are one of the downstream
metabolites of tryptophan (62,63).
The fact that CHOP did not seem to play a role in the responsiveness of IDO KO
T-cells and their WT counterparts is also surprising, given that this protein was used as
part of a reporter system to study IDO expression in another study (39). Since CHOP
expression is linked to GCN2 kinase activation, which in itself senses amino acid stress
inside a cell (34), it is logical that IDO KO CTLs would exhibit lower levels of CHOP
because of the absence of tryptophan degradation through EDO. However, it is possible
that the level of amino acid stress in WT CTLs caused by physiological IDO expression
was not enough to induce elevated CHOP levels in this system, which is why there was
no difference between IDO KO and WT mice in the context of CHOP expression.
One important limitation to consider is that all experiments here were conducted
in a mouse model, and more research is required in order to elucidate whether the
findings are applicable to humans. In fact, a vast proportion of published literature on the
subject of IDO mediated immune modulation is based on the mouse system
(31,34,35,38,53,69,71). Therefore, it is crucial to consider that murine IDO differs from
its human ortholog in a variety of different aspects, not the least of which is their genetic
sequence. Mouse IDO (407 amino acids) and human IDO (403 amino acids) only share
62% sequence identity, which is comparably low amongst other enzymes in the Lkynurenine pathway. In addition, recombinant mouse IDO remains significantly more
active at alkaline pH when compared with human EDO, and also exhibits a three-fold
higher substrate efficiency ratio for L-tryptophan (72). Therefore future work will have to
take these differences into account and ensure that findings using the mouse system are
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also relevant to humans. This is particularly important because a Phase 1 clinical trial of
the IDO inhibitor 1-MT is already underway (H.Lee Moffat Cancer Center and Research
Institute: NCT00617422) in a subset of cancer patients, but the basic science behind the
trial may not be perfectly sound yet.
It is also important to note that a paralog of the EDO was recently discovered and
termed IDO-2 (73). The capacity of this new enzyme to degrade tryptophan differs from
IDO-1, as does its tissue and cell distribution. IDO-2 is primarily expressed in the
reproductive tract, liver, and kidneys, and the two IDO paralogs exhibit 42% similarity in
amino acid sequence (74). In addition, IDO-2 is able to function at more alkaline pH than
IDO-1 (global maximum pH 7.5 for IDO-2 and 6-6.5 for IDO-1) which is consistent with
the reported pH in the tissues in which IDO-2 is expressed (i.e., seminiferous tubules pH
7.2-8.0). Furthermore, the reduced substrate activity of IDO-2 when compared with IDO1 may be due to an amino acid mutation in the catalytic pocket of the enzyme (F227 to
Y231) which makes it prone to phosphorylation or sulfation. In both humans and mice,
the two IDO genes are located adjacent to each other on chromosome 8, suggesting that a
gene duplication event may be responsible for the presence of either gene (29).
Importantly, the functional significance of IDO-2, especially in the realm of
immune regulation, is an active field of investigation still in its infancy. The IDO KO
mice used in this study were missing the IDO-1 enzyme and not its paralog, which calls
into question the relevance of this newly discovered IDO-2 molecule. It is still possible
however, that in the complete absence of both IDO paralogs CTL responses would be
even more enhanced than in animals without IDO-1 only. For instance, it would be
interesting to determine the effect of this double knockout on susceptibility to intranasal
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IAV, and investigate whether it is protective, unlike IDO-1 KO. However, given the
unique tissue expression profile of IDO-2, it is less likely to play a role in global immune
regulation than IDO-1 and may be more important in maternal fetal tolerance instead.
Though the role of IDO mediated tryptophan metabolism in CTL immunobiology
is of clinical interest and import, much work remains to be done to generate a unified
model of T-cell regulation by this enzyme, especially in the realm of viral infection.
Taking the differences between humans and mice into account, and also further
investigating the function of IDO-2, may illuminate a previously unappreciated facet of
CTL regulation.
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